Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

@article{Am2004ContrastingNA,
  title={Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline},
  author={Orit Bar Am and Tamar Amit and Moussa B. H. Youdim},
  journal={Neuroscience Letters},
  year={2004},
  volume={355},
  pages={169-172}
}
The anti-Parkinson selective irreversible monoamine oxidase B inhibitor drugs, rasagiline and selegiline, have been shown to possess neuroprotective activities in cell culture and in vivo models. While rasagiline is metabolized to its major metabolite aminoindan, selegiline gives rise to L-methamphetamine. Cultured PC-12 cells in absence of serum and nerve growth factor (NGF) die by an apoptotic process. Pretreatment of PC12 cells in absence of serum and NGF for 24 h with either rasagiline (1… 
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives
TLDR
Structural activity studies have shown that the neuroprotective activity is associated with the propargyl moiety of rasagiline which protects mitochondrial viability and MPTp by activating Bcl-2 and protein kinase C (PKC), and down regulating pro-apoptotic FAS and Bax.
Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity
TLDR
It is demonstrated that the major metabolite of rasagiline, 1-(R)-aminoindan has antioxidant and neuroprotective capabilities and thus, may contribute to the overt activity of its parent compound, rasgiline.
Rasagiline: an anti-Parkinson drug with neuroprotective activity
  • M. Youdim
  • Chemistry, Medicine
    Expert review of neurotherapeutics
  • 2003
TLDR
Rasagiline is a novel neuroprotective–antiapoptotic second-generation potent irreversible selective inhibitor of monoamine oxidase B that prevents the neurotoxin-initiated demise of mitochondria via modulation of cell survival/death Bcl-2 family proteins at the mitochondria permeability transition pore.
BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson׳s disease
TLDR
Evidence is provided of neuroprotection by aminoindan and rasagiline via their ability to enhance BDNF levels and a sparing in the mitochondrial marker Hsp60, suggesting mitochondrial involvement in neuroprotection.
Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?
TLDR
Rasagiline has been recently evaluated in early PD patients, with results that are consistent with slowing the progression of the disease, thus providing new perspectives for the treatment of PD.
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro
TLDR
The findings suggest that both metabolites may contribute to the overall neuroprotective activity of their respective parent compounds, further implicating rasagiline and ladostigil as potentially valuable drugs for treatment of a wide variety of neurodegenerative disorders of aging.
Multi Target Neuroprotective and Neurorestorative Anti-Parkinson and Anti-Alzheimer Drugs Ladostigil and M30 Derived from Rasagiline
  • M. Youdim
  • Medicine
    Experimental neurobiology
  • 2013
TLDR
A series of novel multi-functional neuroprotective drugs with unique multiple actions of ladostigil and M30 make the potentially useful drugs for the treatment of dementia with Parkinsonian-like symptoms and depression.
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin‐induced nigrostriatal dopaminergic degeneration
TLDR
Compared with selegiline, rasagiline is more potent in protecting neurodegeneration induced by UPS impairment and may, therefore, exert disease‐modifying effects in PD.
Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease
TLDR
Recent advances in understanding of the neuroprotection offered by MAOB-Is are presented and possible evaluation of neuroprotective efficacy in clinical samples is discussed.
Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms
TLDR
The authors review their recent results on the molecular mechanisms by which MAO inhibitors prevent the cell death through the induction of antiapoptotic, prosurvival genes in selegiline and rasagiline.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells.
TLDR
There may be a neuroprotective advantage of rasagiline over selegiline, according to the results of the present study, which indicates that L-methamphetamine, but not 1-R-aminoindan, blocked the neuroProtective effect of the parental drug.
The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo
TLDR
Neither TVP1022 nor TV3219 are MAO inhibitors, both share the antiapoptotic and neuroprotective actions of rasagiline, indicating that MAO inhibition is not a prerequisite for neuroprotection and that the propargyl moiety exhibits intrinsic neuroProtective pharmacological activity that requires identification.
Molecular Basis of Neuroprotective Activities of Rasagiline and the Anti-Alzheimer Drug TV3326 [lpar;N-Propargyl-(3R) Aminoindan-5-YL)-Ethyl Methyl Carbamate]
TLDR
Rasagiline, TV3326 and TV3279 are able to influence the processing of amyloid precursor protein by activation of alpha-secretase and increasing the release of soluble alpha APP in rat PC-12 and human neuroblastoma SH-SY5Y cells and in rat and mice cortex and hippocampus.
Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours
TLDR
Rasagiline does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but notMAO-A, and does not induce the behavioural hyperactivity syndrome.
Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor
TLDR
A series of novel propargylaminoindans with a carbamate moiety to inhibit cholinesterase were developed from phamacophore of rasagiline to protect or rescue deteriorated neurons in Alzheimer's and Lewy Body disease and provide a beneficial effect on the cognitive deficits.
The importance of propargylamine moiety in the anti‐ Parkinson drug rasagiline and its derivatives for MAPK‐ dependent amyloid precursor protein processing
TLDR
It is demonstrated that MAO‐B inhibition is not a prerequisite for either sAPPα‐induced release or ERK phosphorylation, and structure‐activity relationship among rasagiline‐related compounds suggests the crucial role of the propargyl moiety in these molecules.
The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.
TLDR
Results have provided a new understanding into the mechanism of neuroprotective actions of rasagiline and its anti-Alzheimer drug derivatives TV3326 and TV3279, which are relevant for therapy of Parkinson's disease, Alzheimer's disease and other neurodegenerative diseases.
Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022.
TLDR
It is suggested that mitochondria regulate apoptotic process, which may be a target of neuroprotection by rasagiline, a selective irreversible inhibitor of type B monoamine oxidase to prevent the cell death.
Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation
TLDR
Examination of the effect of flupirtine on methamphetamine toxicity in mice and the influence on dopamine release and free radical formation in the rat striatum by microdialysis suggests that other mechanisms rather than dopamine metabolism and autoxidation may contribute to methamphetamine neurotoxicity.
Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat
TLDR
Rasagiline in repeat ip doses of 1–3 mg/kg within 16 h, or by sustained iv infusion to maintain a 3-h steady-state at corresponding levels, improved the outcome of permanent middle cerebral artery occlusion (MCAO) in the rat.
...
1
2
...